肾素-血管紧张素-醛固酮系统抑制加重镰状细胞病贫血
该研究通过横断面分析、纵向队列和动物实验探讨RAASi对镰状细胞病贫血的影响。横断面分析显示RAASi使用与较低血红蛋白浓度独立相关;两个纵向队列中RAASi治疗导致血红蛋白较治疗前下降;镰状细胞病小鼠实验显示氯沙坦降低血红蛋白和网织红细胞计数,并影响红系集落形成。建议在高风险人群中使用RAASi时密切监测血红蛋白水平。
要点
- RAASi使用与镰状细胞病患者较低血红蛋白浓度独立相关。
- 纵向队列显示RAASi治疗导致血红蛋白较治疗前下降。
- 镰状细胞病小鼠中氯沙坦降低血红蛋白和网织红细胞计数。
核心结论
- RAASi使用与镰状细胞病患者血红蛋白浓度降低独立相关,并可能导致贫血加重。
研究设计与样本
- 横断面分析纳入658名Walk-PHaSST参与者;两个纵向队列分别来自伊利诺伊大学芝加哥分校(n=24)和多中心氯沙坦临床试验(n=32);另进行镰状细胞病小鼠实验。
临床怎么用
- 在镰状细胞病患者中使用RAASi时应密切监测血红蛋白水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Renin-angiotensin-aldosterone system inhibitors (RAASi) are suggested for treating albuminuria in patients with sickle cell disease (SCD). RAASi may exacerbate anemia in the general population and those with diabetes through unclear mechanisms. The impact of RAASi on anemia in chronic hemolytic disorders, such as SCD, is unknown. In a cross-sectional analysis of 658 Walk-PHaSST participants, RAASi use was independently associated with lower hemoglobin concentrations, adjusting for age, sex, SCD genotype, estimated glomerular filtration rate, and erythroid-stimulating agent and hydroxyurea use (β, -0.46 ± 0.21; P = .032). In 2 longitudinal cohorts (University of Illinois Chicago, n = 24; multicenter losartan clinical trial, n = 32), RAASi therapy led to a reduction in hemoglobin concentrations compared with pretreatment values by -0.44 ± 0.14 g/dL (P = .006) and -0.53 ± 0.17 g/dL (P = .005), respectively. SCD mice treated with losartan demonstrated lower hemoglobin concentrations after 6 and 14 weeks (P< .001) and lower absolute reticulocyte counts by 14 weeks (P = .03) vs control mice without changes in circulating erythropoietin, interleukin-12p70 (IL-12p70), IL-3, or insulin-like growth factor 1 levels. Bone marrow cells from losartan-treated SCD mice had lower colony-forming units (P ≤ .09) with rescue of erythroid colony formation after exogenous erythropoietin supplementation (P = .02). Bone marrow histopathology demonstrated reduced erythroid relative to myeloid ratios in losartan-treated vs untreated SCD mice. Hemoglobin levels should be closely monitored when using RAASi in this high-risk population.
引用
- Eskandari N, Pappano E, Ruiz MA, et al. Renin-angiotensin-aldosterone system inhibition exacerbates anemia in sickle cell disease. Blood. 2026. PMID: 42224366. doi:10.1182/blood.2026033813
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。